Wedbush Reiterates an 'Outperform' on Pharmacyclics (PCYC); Expect Ibrutinib to Dominate CLL Treatment
Tweet Send to a Friend
Wedbush reiterates an 'Outperform' on Pharmacyclics (NASDAQ: PCYC) price target of $93.00 (from $55.00).
Analyst, Gregory R. Wade, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Gregory R. Wade, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
